MicroRNA control of epithelial-mesenchymal transition in cancer stem cells

International Journal of Cancer

Volumn 135, Issue 5, 2014, Pages 1019-1027

  Hao, Jin ^a   Zhang, Yueling ^a   Deng, Mengzhao ^a   Ye, Rui ^a   Zhao, Sen ^a   Wang, Yating ^a   Li, Juan ^a   Zhao, Zhihe ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

cancer stem cells; cancer therapy; epithelial mesenchymal transition; microRNA

Indexed keywords

MICRORNA;

BINDING SITE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT;

CANCER STEM CELLS; CANCER THERAPY; EPITHELIAL-MESENCHYMAL TRANSITION; MICRORNA;

ANIMALS; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICRORNAS; NEOPLASMS; NEOPLASTIC STEM CELLS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 84902548716     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28761     Document Type: Review

References (130)

1. Visvader JE, Lindeman GJ,. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-28.
2. Visvader JE, Lindeman GJ,. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
4. Yu Z, Pestell TG, Lisanti MP, et al. Cancer stem cells. Int J Biochem Cell Biol 2012; 44: 2144-51.
5. Morel AP, Lievre M, Thomas C, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLOS ONE 2008; 3: e2888.
6. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
7. Kalluri R, Weinberg RA,. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-8.
8. Yin G, Alvero AB, Craveiro V, et al. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 2013; 32: 39-49.
9. Garzon R, Fabbri M, Cimmino A, et al. MicroRNA expression and function in cancer. Trends Mol Med 2006; 12: 580-7.
10. Yu Z, Baserga R, Chen L, et al. microRNA, cell cycle, and human breast cancer. Am J Pathol 2010; 176: 1058-64.
11. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
12. Gregory PA, Bracken CP, Bert AG, et al. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008; 7: 3112-8.
13. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
14. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
15. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
16. Magee JA, Piskounova E, Morrison SJ,. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-96.
17. Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488: 522-6.
18. Driessens G, Beck B, Caauwe A, et al. Defining the mode of tumour growth by clonal analysis. Nature 2012; 488: 527-30.
19. Schepers AG, Snippert HJ, Stange DE, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012; 337: 730-5.
20. Leal JA, Lleonart ME,. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett 2012.
21. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67.
22. Scheel C, Weinberg RA,. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells. Int J Cancer 2011; 129: 2310-4.
23. Boyer B, Valles AM, Edme N,. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 2000; 60: 1091-9.
24. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
25. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-39.
26. Ansieau S, Bastid J, Doreau A, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008; 14: 79-89.
27. Lien HC, Hsiao YH, Lin YS, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 2007; 26: 7859-71.
28. Zavadil J, Bottinger EP,. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-74.
29. Brabletz T,. EMT and MET in metastasis: where are the cancer stem cells. Cancer Cell 2012; 22: 699-701.
30. Song SJ, Poliseno L, Song MS, et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013; 154: 311-24.
31. Hao J, Zhao S, Zhang Y, Zhao Z, Ye R, Wen J, Li J,. Emerging Role of MicroRNAs in Cancer and Cancer Stem Cells. J Cell Biochem 2014; 115 (4): 605-10.
32. Wu CY, Tsai YP, Wu MZ, et al. Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends Genet 2012; 28: 454-63.
33. De Craene B, Berx G,. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13: 97-110.
34. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-9.
35. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
36. Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-4.
37. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
38. Siemens H, Jackstadt R, Hunten S, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10: 4256-71.
39. Brabletz S, Brabletz T,. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer. EMBO Rep 2010; 11: 670-7.
40. Ru P, Steele R, Newhall P, et al. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther 2012; 11: 1166-73.
41. Zhang J, Zhang H, Liu J, et al. miR-30 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1. Biochem Biophys Res Commun 2012; 417: 1100-5.
42. Gandellini P, Giannoni E, Casamichele A, et al. miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. Antioxidant Redox Signal 2013.
43. Liu X, Wang C, Chen Z, Jin Y, et al. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 2011; 440: 23-31.
44. Kim NH, Kim HS, Li XY, et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol 2011; 195: 417-33.
45. Moes M, Le BA, Crespo I, et al. A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLOS ONE 2012; 7: e35440.
46. Kong W, Yang H, He L, et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008; 28: 6773-84.
47. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Natl Cell Biol 2010; 12: 247-56.
48. Meng Z, Fu X, Chen X, et al. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 2010; 52: 2148-57.
49. Song Y, Zhao F, Wang Z, et al. Inverse association between miR-194 expression and tumor invasion in gastric cancer. Ann Surg Oncol 2012; 19 Suppl 3: S509-17.
50. Vetter G, Saumet A, Moes M, et al. miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene 2010; 29: 4436-48.
51. Zhou Q, Fan J, Ding X, et al. TGF-{beta}-induced MiR-491-5p expression promotes Par-3 degradation in rat proximal tubular epithelial cells. J Biol Chem 2010; 285: 40019-27.
52. Hamada S, Satoh K, Miura S, et al. miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol 2013; 228: 1255-63.
53. Rao M,. Conserved and divergent paths that regulate self-renewal in mouse and human embryonic stem cells. Dev Biol 2004; 275: 269-86.
54. Zaidi SK, Van Wijnen AJ, Lian JB, et al. Targeting deregulated epigenetic control in cancer. J Cell Physiol 2013; 228: 2103-8.
55. Liu J, Zheng M, Tang YL, et al. MicroRNAs, an active and versatile group in cancers. Int J Oral Sci 2011; 3: 165-75.
56. Garg M,. MicroRNAs, stem cells and cancer stem cells. World J Stem Cells 2012; 4: 62-70.
57. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLOS ONE 2009; 4: e6816.
58. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-23.
59. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
60. Iliopoulos D, Lindahl-Allen M, Polytarchou C, et al. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010; 39: 761-72.
61. Barroso-del JA, Lucena-Aguilar G, Menendez P,. The miR-302-367 cluster as a potential stemness regulator in ESCs. Cell Cycle 2009; 8: 394-8.
62. Barroso-delJesus A, Romero-Lopez C, Lucena-Aguilar G, et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol 2008; 28: 6609-19.
63. Liu C, Kelnar K, Vlassov AV, et al. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res 2012; 72: 3393-404.
64. Wang L, Zhang D, Zhang C, et al. A microRNA expression signature characterizing the properties of tumor-initiating cells for breast cancer. Oncol Lett 2012; 3: 119-24.
65. Okuda H, Xing F, Pandey PR, et al. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res 2013; 73: 1434-44.
66. Wong P, Iwasaki M, Somervaille TC, et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res 2010; 70: 3833-42.
67. Jia Y, Liu H, Zhuang Q, Xu S, et al. Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep 2012; 27: 1865-72.
68. Yang YP, Chien Y, Chiou GY, et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 2012; 33: 1462-76.
69. Yu XF, Zou J, Bao ZJ, et al. miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J Gastroenterol 2011; 17: 4711-7.
70. de Antonellis P, Medaglia C, Cusanelli E, et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLOS ONE 2011; 6: e24584.
71. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17 (2): 211-5.
72. Nalls D, Tang SN, Rodova M, et al. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLOS ONE 2011; 6: e24099.
73. Yu F, Jiao Y, Zhu Y, et al. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J Biol Chem 2012; 287: 465-73.
74. Yu Y, Kanwar SS, Patel BB, et al. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis 2012; 33: 68-76.
75. Chung WM, Chang WC, Chen L, et al. MicroRNA-21 promotes ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations in vitro. Stem Cell Res Ther 2013; 4: 88.
76. Yu F, Deng H, Yao H, et al. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010; 29: 4194-204.
77. Zhang J, Luo N, Luo Y, et al. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol 2012; 40: 747-56.
78. Godlewski J, Nowicki MO, Bronisz A, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 2008; 68: 9125-30.
79. Zhu Y, Yu F, Jiao Y, et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 2011; 17: 7105-15.
80. Fan X, Chen X, Deng W, et al. Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression. BMC Cancer 2013; 13: 61.
81. Gal H, Pandi G, Kanner AA, Ram Z, et al. MIR-451 and imatinib mesylate inhibit tumor growth of glioblastoma stem cells. Biochem Biophys Res Commun 2008; 376: 86-90.
82. Bitarte N, Bandres E, Boni V, et al. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 2011; 29: 1661-71.
83. Shi L, Zhang J, Pan T, et al. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res 2010; 1312: 120-6.
84. Shi L, Zhang S, Feng K, et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol 2012; 40: 119-29.
85. Otsubo T, Akiyama Y, Hashimoto Y, et al. MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLOS ONE 2011; 6: e16617.
86. Nanta R, Kumar D, Meeker D, et al. NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rgamma null mice by regulating Bmi-1 and microRNA-128. Oncogenesis 2013; 2: e42.
87. Peruzzi P, Bronisz A, Nowicki MO, et al. MicroRNA-128 coordinately targets polycomb repressor complexes in glioma stem cells. Neuro Oncol 2013.
88. Jeon HM, Sohn YW, Oh SY, et al. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9-mediated suppression of SOX2. Cancer Res 2011; 71: 3410-21.
89. Schraivogel D, Weinmann L, Beier D, et al. CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J 2011; 30: 4309-22.
90. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Natl Cell Biol 2009; 11: 1487-95.
91. Xia H, Ng SS, Jiang S, et al. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun 2010; 391: 535-41.
92. Lo WL, Yu CC, Chiou GY, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol 2011; 223: 482-95.
93. Tellez CS, Juri DE, Do K, et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 2011; 71: 3087-97.
94. Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50: 472-80.
95. Wang Y, Yu Y, Tsuyada A, Ren X, et al. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011; 30: 1470-80.
96. Meng F, Glaser SS, Francis H, et al. Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med 2012; 16: 160-73.
97. Yang X, Lin X, Zhong X, Kaur S, et al. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 2010; 70: 9463-72.
98. Hwang-Verslues WW, Chang PH, Wei PC, et al. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 2011; 30: 2463-74.
99. Ma S, Tang KH, Chan YP, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010; 7: 694-707.
100. Babashah S, Sadeghizadeh M, Hajifathali A, et al. Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells. Int J Cancer 2013; 133: 579-89.
101. Li WQ, Li YM, Tao BB, et al. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit 2010; 16: HY27-30.
102. Garzia L, Andolfo I, Cusanelli E, et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLOS ONE 2009; 4: e4998.
103. Silber J, Lim DA, Petritsch C, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008; 6: 14.
104. Xia H, Cheung WK, Ng SS, Jiang X, Jiang S, Sze J, Leung GK, Lu G, Chan DT, Bian XW, Kung HF, Poon WS, et al. Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells. J Biol Chem 2012; 287 (13): 9962-71.
105. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011; 108: 7950-5.
106. Gupta PB, Fillmore CM, Jiang G, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146: 633-44.
107. Yang G, Quan Y, Wang W, et al. Dynamic equilibrium between cancer stem cells and non-stem cancer cells in human SW620 and MCF-7 cancer cell populations. Br J Cancer 2012; 106: 1512-9.
108. Gregory PA, Bracken CP, Smith E, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011; 22: 1686-98.
109. Chaffer CL, Marjanovic ND, Lee T, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61-74.
110. Yang MH, Hsu DS, Wang HW, et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010; 12: 982-92.
111. Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLOS ONE 2010; 5: e12445.
112. Chang CJ, Chao CH, Xia W, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 317-23.
113. Chen D, Zhang Y, Wang J, et al. MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J Ovarian Res 2013; 6: 50.
114. Han M, Liu M, Wang Y, et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLOS ONE 2012; 7: e39520.
115. Samavarchi-Tehrani P, Golipour A, David L, et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010; 7: 64-77.
116. Celia-Terrassa T, Meca-Cortes O, Mateo F, et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 2012; 122: 1849-68.
117. Ocana OH, Corcoles R, Fabra A, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012; 22: 709-24.
118. Tsai JH, Donaher JL, Murphy DA, et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22: 725-36.
119. Chang CJ, Hsu CC, Chang CH, et al. Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol Rep 2011; 26: 1003-10.
120. Bao B, Wang Z, Ali S, et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 2011; 112: 2296-306.
121. Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011; 307: 26-36.
122. Han M, Wang Y, Liu M, et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1alpha expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci 2012; 103: 1058-64.
123. Turcatel G, Rubin N, El-Hashash A, et al. MIR-99a and MIR-99b modulate TGF-beta induced epithelial to mesenchymal plasticity in normal murine mammary gland cells. PLOS ONE 2012; 7: e31032.
124. Smith AL, Iwanaga R, Drasin DJ, et al. The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 2012; 31: 5162-71.
125. Dong P, Kaneuchi M, Watari H, et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 2011; 10: 99.
126. Xia H, Cheung WK, Sze J, et al. miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. J Biol Chem 2010; 285: 36995-7004.
127. Iliopoulos D, Polytarchou C, Hatziapostolou M, et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2009; 2: ra62.
128. Guttilla IK, Phoenix KN, Hong X, et al. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat 2012; 132: 75-85.
129. Singh A, Settleman J,. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-51.
130. Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 2012; 22: 194-207.